Nateglinide

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Insulin Resistance

Conditions

Insulin Resistance, Impaired Fasting Glucose

Trial Timeline

Jun 1, 2003 → Mar 1, 2006

NCT ID

NCT00259168

About Nateglinide

Nateglinide is a approved stage product being developed by Novartis for Insulin Resistance. The current trial status is completed. This product is registered under clinical trial identifier NCT00259168. Target conditions include Insulin Resistance, Impaired Fasting Glucose.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00402909	Approved	Completed	Nov 1, 2006	Aug 1, 2007	Type 2 Diabetes
NCT00259168	Approved	Completed	Jun 1, 2003	Mar 1, 2006	Insulin Resistance
NCT00238472	Approved	Completed	May 1, 2003	Jun 1, 2005	Diabetes Mellitus, Type 2

Competing Products

20 competing products in Insulin Resistance

See all competitors

Product	Company	Stage	Hype Score
naveglitazar	Eli Lilly	Phase 2	52
AC2993 + AC2993 + Placebo + Placebo	AstraZeneca	Phase 3	77
Dapagliflozin 10 mg + Placebo tablet	AstraZeneca	Phase 3	77
Placebo 0.01 mL + Placebo 0.02 mL + Placebo 0.03 mL + Placebo 0.04 mL + AC2993 2.5 mcg + AC2993 5.0 mcg + AC2993 7.5 mcg + AC2993 10.0 mcg	AstraZeneca	Phase 2	52
Atropine + Physostigmine + Placebo Sodium	AstraZeneca	Phase 1	33
Saxagliptin	AstraZeneca	Approved	85
AC2993 + AC2993 + Placebo + Placebo	AstraZeneca	Phase 3	77
Pramlintide acetate	AstraZeneca	Phase 2	52
sitagliptin + Comparator: glimepiride + open-label metformin	Merck	Phase 3	77
sitagliptin	Merck	Approved	85
sitagliptin phosphate	Merck	Phase 3	77
MK-1006 + Placebo	Merck	Phase 1	33
Comparator: Placebo + Sitagliptin + Voglibose	Merck	Phase 3	77
sitagliptin phosphate + Comparator: metformin + Comparator: metformin + Comparator: Antidiabetic Standard of Care	Merck	Phase 3	77
Placebo + MK-0941	Merck	Phase 1	33
Placebo + Prednisolone	Merck	Pre-clinical	23
Comparator: exenatide + Comparator: exenatide + Comparator: Placebo	Merck	Phase 1	33
simvastatin/ezetimibe + atorvastatin 20mg	Merck	Approved	85
sitagliptin phosphate + Comparator: Placebo + Comparator: Sitagliptin	Merck	Phase 2	52
sitagliptin phosphate	Merck	Phase 1	33

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

TenofovirApproved

FTY720Approved

150 mg open-label secukinumab + 150 mg double-blinded secukinumab + 300 mg double-blinded secukinumabApproved